Loading…

Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging

Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retai...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry 2018-06, Vol.293 (23), p.9030-9040
Main Authors: Long, Nicholas E., Sullivan, Brandon J., Ding, Haiming, Doll, Stephanie, Ryan, Michael A., Hitchcock, Charles L., Martin, Edward W., Kumar, Krishan, Tweedle, Michael F., Magliery, Thomas J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453
cites cdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453
container_end_page 9040
container_issue 23
container_start_page 9030
container_title The Journal of biological chemistry
container_volume 293
creator Long, Nicholas E.
Sullivan, Brandon J.
Ding, Haiming
Doll, Stephanie
Ryan, Michael A.
Hitchcock, Charles L.
Martin, Edward W.
Kumar, Krishan
Tweedle, Michael F.
Magliery, Thomas J.
description Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.
doi_str_mv 10.1074/jbc.RA118.002538
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5995523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021925820372148</els_id><sourcerecordid>29669811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi1ERZfCnRPyAzRb20nWMQekVQUFaSWkqpV6sxx7kkxJ7MjOVloegaeu6UIFB3wZj2f-fzz6CHnH2ZozWV3ct3Z9veW8WTMm6rJ5QVacNWVR1vzuJVnlR14oUTen5HVK9yyfSvFX5FSozUY1nK_Izx367xAp-B49QETfU_TU-AWLm-1VIcXTvQ3uQLto-gn8kmiYF5zwByTaYpiHQ0JrRjrHMENcENI5TRD3Ex3M2BUjdnCeXRwdsB-KNIPFDi0uB7rspxApTiYP79-Qk86MCd7-jmfk9vOnm8svxe7b1dfL7a6wVSWXQtlNC46pRhilpKwsc9KZjZCdrFqlKlmL2glRV23TNIq5KmeKtUYaZV3OyjPy8eg779sJnM0bRTPqOeZ_xIMOBvW_FY-D7sODrpWqa1FmA3Y0sDGkFKF71nKmf3HRmYt-4qKPXLLk_d8znwV_QOSGD8cGyJs_IESdLIK34DCCXbQL-H_3R0C6oO0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</title><source>PubMed (Medline)</source><source>ScienceDirect®</source><creator>Long, Nicholas E. ; Sullivan, Brandon J. ; Ding, Haiming ; Doll, Stephanie ; Ryan, Michael A. ; Hitchcock, Charles L. ; Martin, Edward W. ; Kumar, Krishan ; Tweedle, Michael F. ; Magliery, Thomas J.</creator><creatorcontrib>Long, Nicholas E. ; Sullivan, Brandon J. ; Ding, Haiming ; Doll, Stephanie ; Ryan, Michael A. ; Hitchcock, Charles L. ; Martin, Edward W. ; Kumar, Krishan ; Tweedle, Michael F. ; Magliery, Thomas J.</creatorcontrib><description>Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.</description><identifier>ISSN: 0021-9258</identifier><identifier>EISSN: 1083-351X</identifier><identifier>DOI: 10.1074/jbc.RA118.002538</identifier><identifier>PMID: 29669811</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antibody Affinity ; antibody engineering ; Antigens, Neoplasm - analysis ; Antigens, Neoplasm - immunology ; Cell Line, Tumor ; Cloning, Molecular ; colorectal cancer ; drug development ; Female ; Glycoproteins - analysis ; Glycoproteins - immunology ; Humans ; immunohistochemistry ; in vivo imaging ; Mice ; Mice, Inbred BALB C ; mucin ; Neoplasms - diagnostic imaging ; oligomerization ; Positron-Emission Tomography ; Protein Engineering ; protein stability ; Protein Structure and Folding ; Single-Chain Antibodies - blood ; Single-Chain Antibodies - genetics ; Single-Chain Antibodies - immunology ; Single-Chain Antibodies - pharmacokinetics ; Tissue Distribution ; tumor marker</subject><ispartof>The Journal of biological chemistry, 2018-06, Vol.293 (23), p.9030-9040</ispartof><rights>2018 © 2018 Long et al.</rights><rights>2018 Long et al.</rights><rights>2018 Long et al. 2018 Long et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</citedby><cites>FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</cites><orcidid>0000-0003-0779-1477</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995523/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021925820372148$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29669811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Long, Nicholas E.</creatorcontrib><creatorcontrib>Sullivan, Brandon J.</creatorcontrib><creatorcontrib>Ding, Haiming</creatorcontrib><creatorcontrib>Doll, Stephanie</creatorcontrib><creatorcontrib>Ryan, Michael A.</creatorcontrib><creatorcontrib>Hitchcock, Charles L.</creatorcontrib><creatorcontrib>Martin, Edward W.</creatorcontrib><creatorcontrib>Kumar, Krishan</creatorcontrib><creatorcontrib>Tweedle, Michael F.</creatorcontrib><creatorcontrib>Magliery, Thomas J.</creatorcontrib><title>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</title><title>The Journal of biological chemistry</title><addtitle>J Biol Chem</addtitle><description>Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.</description><subject>Animals</subject><subject>Antibody Affinity</subject><subject>antibody engineering</subject><subject>Antigens, Neoplasm - analysis</subject><subject>Antigens, Neoplasm - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cloning, Molecular</subject><subject>colorectal cancer</subject><subject>drug development</subject><subject>Female</subject><subject>Glycoproteins - analysis</subject><subject>Glycoproteins - immunology</subject><subject>Humans</subject><subject>immunohistochemistry</subject><subject>in vivo imaging</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>mucin</subject><subject>Neoplasms - diagnostic imaging</subject><subject>oligomerization</subject><subject>Positron-Emission Tomography</subject><subject>Protein Engineering</subject><subject>protein stability</subject><subject>Protein Structure and Folding</subject><subject>Single-Chain Antibodies - blood</subject><subject>Single-Chain Antibodies - genetics</subject><subject>Single-Chain Antibodies - immunology</subject><subject>Single-Chain Antibodies - pharmacokinetics</subject><subject>Tissue Distribution</subject><subject>tumor marker</subject><issn>0021-9258</issn><issn>1083-351X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kcFu1DAQhi1ERZfCnRPyAzRb20nWMQekVQUFaSWkqpV6sxx7kkxJ7MjOVloegaeu6UIFB3wZj2f-fzz6CHnH2ZozWV3ct3Z9veW8WTMm6rJ5QVacNWVR1vzuJVnlR14oUTen5HVK9yyfSvFX5FSozUY1nK_Izx367xAp-B49QETfU_TU-AWLm-1VIcXTvQ3uQLto-gn8kmiYF5zwByTaYpiHQ0JrRjrHMENcENI5TRD3Ex3M2BUjdnCeXRwdsB-KNIPFDi0uB7rspxApTiYP79-Qk86MCd7-jmfk9vOnm8svxe7b1dfL7a6wVSWXQtlNC46pRhilpKwsc9KZjZCdrFqlKlmL2glRV23TNIq5KmeKtUYaZV3OyjPy8eg779sJnM0bRTPqOeZ_xIMOBvW_FY-D7sODrpWqa1FmA3Y0sDGkFKF71nKmf3HRmYt-4qKPXLLk_d8znwV_QOSGD8cGyJs_IESdLIK34DCCXbQL-H_3R0C6oO0</recordid><startdate>20180608</startdate><enddate>20180608</enddate><creator>Long, Nicholas E.</creator><creator>Sullivan, Brandon J.</creator><creator>Ding, Haiming</creator><creator>Doll, Stephanie</creator><creator>Ryan, Michael A.</creator><creator>Hitchcock, Charles L.</creator><creator>Martin, Edward W.</creator><creator>Kumar, Krishan</creator><creator>Tweedle, Michael F.</creator><creator>Magliery, Thomas J.</creator><general>Elsevier Inc</general><general>American Society for Biochemistry and Molecular Biology</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0779-1477</orcidid></search><sort><creationdate>20180608</creationdate><title>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</title><author>Long, Nicholas E. ; Sullivan, Brandon J. ; Ding, Haiming ; Doll, Stephanie ; Ryan, Michael A. ; Hitchcock, Charles L. ; Martin, Edward W. ; Kumar, Krishan ; Tweedle, Michael F. ; Magliery, Thomas J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Antibody Affinity</topic><topic>antibody engineering</topic><topic>Antigens, Neoplasm - analysis</topic><topic>Antigens, Neoplasm - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cloning, Molecular</topic><topic>colorectal cancer</topic><topic>drug development</topic><topic>Female</topic><topic>Glycoproteins - analysis</topic><topic>Glycoproteins - immunology</topic><topic>Humans</topic><topic>immunohistochemistry</topic><topic>in vivo imaging</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>mucin</topic><topic>Neoplasms - diagnostic imaging</topic><topic>oligomerization</topic><topic>Positron-Emission Tomography</topic><topic>Protein Engineering</topic><topic>protein stability</topic><topic>Protein Structure and Folding</topic><topic>Single-Chain Antibodies - blood</topic><topic>Single-Chain Antibodies - genetics</topic><topic>Single-Chain Antibodies - immunology</topic><topic>Single-Chain Antibodies - pharmacokinetics</topic><topic>Tissue Distribution</topic><topic>tumor marker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Long, Nicholas E.</creatorcontrib><creatorcontrib>Sullivan, Brandon J.</creatorcontrib><creatorcontrib>Ding, Haiming</creatorcontrib><creatorcontrib>Doll, Stephanie</creatorcontrib><creatorcontrib>Ryan, Michael A.</creatorcontrib><creatorcontrib>Hitchcock, Charles L.</creatorcontrib><creatorcontrib>Martin, Edward W.</creatorcontrib><creatorcontrib>Kumar, Krishan</creatorcontrib><creatorcontrib>Tweedle, Michael F.</creatorcontrib><creatorcontrib>Magliery, Thomas J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of biological chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Long, Nicholas E.</au><au>Sullivan, Brandon J.</au><au>Ding, Haiming</au><au>Doll, Stephanie</au><au>Ryan, Michael A.</au><au>Hitchcock, Charles L.</au><au>Martin, Edward W.</au><au>Kumar, Krishan</au><au>Tweedle, Michael F.</au><au>Magliery, Thomas J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging</atitle><jtitle>The Journal of biological chemistry</jtitle><addtitle>J Biol Chem</addtitle><date>2018-06-08</date><risdate>2018</risdate><volume>293</volume><issue>23</issue><spage>9030</spage><epage>9040</epage><pages>9030-9040</pages><issn>0021-9258</issn><eissn>1083-351X</eissn><abstract>Antibody (Ab) fragments have great clinical potential as cancer therapeutics and diagnostics. Their small size allows for fast clearance from blood, low immunoreactivity, better tumor penetration, and simpler engineering and production. The smallest fragment derived from a full-length IgG that retains binding to its antigen, the single-chain variable fragment (scFV), is engineered by fusing the variable light and variable heavy domains with a peptide linker. Along with switching the domain orientation, altering the length and amino acid sequence of the linker can significantly affect scFV binding, stability, quaternary structure, and other biophysical properties. Comprehensive studies of these attributes in a single scaffold have not been reported, making design and optimization of Ab fragments challenging. Here, we constructed libraries of 3E8, an Ab specific to tumor-associated glycoprotein 72 (TAG-72), a mucinous glycoprotein overexpressed in 80% of adenocarcinomas. We cloned, expressed, and characterized scFVs, diabodies, and higher-order multimer constructs with varying linker compositions, linker lengths, and domain orientations. These constructs dramatically differed in their oligomeric states and stabilities, not only because of linker and orientation but also related to the purification method. For example, protein L–purified constructs tended to have broader distributions and higher oligomeric states than has been reported previously. From this library, we selected an optimal construct, 3E8.G4S, for biodistribution and pharmacokinetic studies and in vivo xenograft mouse PET imaging. These studies revealed significant tumor targeting of 3E8.G4S with a tumor-to-background ratio of 29:1. These analyses validated 3E8.G4S as a fast, accurate, and specific tumor-imaging agent.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29669811</pmid><doi>10.1074/jbc.RA118.002538</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0779-1477</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9258
ispartof The Journal of biological chemistry, 2018-06, Vol.293 (23), p.9030-9040
issn 0021-9258
1083-351X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5995523
source PubMed (Medline); ScienceDirect®
subjects Animals
Antibody Affinity
antibody engineering
Antigens, Neoplasm - analysis
Antigens, Neoplasm - immunology
Cell Line, Tumor
Cloning, Molecular
colorectal cancer
drug development
Female
Glycoproteins - analysis
Glycoproteins - immunology
Humans
immunohistochemistry
in vivo imaging
Mice
Mice, Inbred BALB C
mucin
Neoplasms - diagnostic imaging
oligomerization
Positron-Emission Tomography
Protein Engineering
protein stability
Protein Structure and Folding
Single-Chain Antibodies - blood
Single-Chain Antibodies - genetics
Single-Chain Antibodies - immunology
Single-Chain Antibodies - pharmacokinetics
Tissue Distribution
tumor marker
title Linker engineering in anti-TAG-72 antibody fragments optimizes biophysical properties, serum half-life, and high-specificity tumor imaging
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T11%3A02%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Linker%20engineering%20in%20anti-TAG-72%20antibody%20fragments%20optimizes%20biophysical%20properties,%20serum%20half-life,%20and%20high-specificity%20tumor%20imaging&rft.jtitle=The%20Journal%20of%20biological%20chemistry&rft.au=Long,%20Nicholas%20E.&rft.date=2018-06-08&rft.volume=293&rft.issue=23&rft.spage=9030&rft.epage=9040&rft.pages=9030-9040&rft.issn=0021-9258&rft.eissn=1083-351X&rft_id=info:doi/10.1074/jbc.RA118.002538&rft_dat=%3Cpubmed_cross%3E29669811%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-9c6bed0982a99774c0d7da627f74b9947525d2254b88890d45d290ba7a9cdd453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29669811&rfr_iscdi=true